

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 8/29/2024
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

UGT1A1 Sequencing

ARUP test code 3004386

UGT1A1 Specimen whole Blood

UGT1A1 Interp

Negative

RESULT

No pathogenic variants were detected in the UGT1A1 gene.

INTERPRETATION

No pathogenic variants were detected in the UGT1A1 gene or the polymorphic (TA)_nTAA promoter region. Two copies of the *1 (TA)₆ allele were detected. The *1 allele is associated with normal UGT1A1 enzyme level. This result decreases the likelihood of but does not exclude a diagnosis of Gilbert or Crigler-Najjar syndromes.

If this test was ordered for pharmacogenetics indication, please refer to clinical guidelines for genotype-based dosing recommendations published by the Clinical Pharmacogenetic Implementation Consortium (CPIC) located at: <https://cpicpgx.org/guidelines/>.

Please refer to the background information included in this report for the methodology and limitations of this test.

RECOMMENDATIONS

Medical management should rely on clinical findings and family history. If this individual has a family history, determination of a causative familial variant in an affected family member is necessary for optimal interpretation of this negative result. Further testing may be warranted if there is a familial variant that is not detectable by this assay. Genetic consultation is recommended.

COMMENTS

Likely benign and benign variants other than the (TA)_nTAA promoter polymorphism are not reported. Variants in the following region(s) may not be detected by NGS with sufficient confidence in this sample due to technical limitations: None

This result has been reviewed and approved by [REDACTED]

BACKGROUND INFORMATION: UGT1A1 Sequencing

CHARACTERISTICS: UGT1A1 encodes the bilirubin uridine diphosphate glucuronosyl transferase 1A1 enzyme, which is responsible for the metabolism of drugs (e.g., irinotecan) and endogenous compounds (e.g., bilirubin). UGT1A1 deficiency is associated with inherited nonhemolytic unconjugated hyperbilirubinemia and a spectrum of

H=High, L=Low, *=Abnormal, C=Critical

phenotypes dependent on the level of residual enzyme activity. Crigler-Najjar syndrome type I results from absent enzyme activity and severe unconjugated hyperbilirubinemia causing jaundice and risk for kernicterus. Crigler-Najjar syndrome type II is associated with reduced hepatic enzyme activity, intermediate levels of hyperbilirubinemia, and low risk for kernicterus. Gilbert syndrome is clinically benign and associated with mild, fluctuating hyperbilirubinemia, which can be caused by impaired bilirubin glucuronidation. Pathogenic UGT1A1 variants are also associated with an increased risk for irinotecan toxicity (neutropenia and diarrhea) and bilirubin-related discontinuation of atazanavir.

EPIDEMIOLOGY: Incidence of Crigler-Najjar syndrome is estimated at 1 in 1 million newborns worldwide. Approximately 3-7 percent of individuals in the U.S. have Gilbert syndrome.

Estimated risk of irinotecan toxicity by genotype in Caucasian patients with colorectal cancer (PMID: 23529007).

(TA)6/6 (*1/*1): diarrhea 15 percent; neutropenia 11 percent.

(TA)6/7 (*1/*28): diarrhea OR=1.20; neutropenia OR=1.90.

(TA)7/7 (*28/*28): diarrhea OR=1.84; neutropenia OR=4.79.

Risks for bilirubin-related atazanavir discontinuation by predicted UGT1A1 phenotype (PMID: 26417955):

Poor metabolizer (*28/*28, *28/*37, *37/*37): 20-60 percent.

Intermediate metabolizer (*1/*28, *1/*37, *36/*28, *36/*37): less than 5 percent.

Extensive or normal metabolizer (*1/*1, *1/*36, *36/*36): less than 5 percent.

CAUSE: Two pathogenic UGT1A1 variants on opposite chromosomes. A variable number of TA repeats in the (TA)_nTAA element of the UGT1A1 promoter affects transcription efficiency. The common number of repeats is six (TA)₆, *1 allele, while seven repeats (TA)₇, *28 allele is associated with reduced transcription activity.

INHERITANCE: Autosomal recessive for Crigler-Najjar and Gilbert syndromes.

CLINICAL SENSITIVITY: Unknown for Crigler-Najjar and Gilbert syndromes.

GENE TESTED: UGT1A1 (NM_000463), promoter (NC_000002). Deletion/duplication analysis is not available for this gene.

METHODOLOGY: Capture of all coding exons and exon-intron junctions of the UGT1A1 gene, including the (TA)_nTAA promoter region, followed by massively parallel sequencing. Sanger sequencing was performed as necessary to fill in regions of low coverage and confirm reported variants.

ANALYTICAL SENSITIVITY/SPECIFICITY: The analytical sensitivity of this test is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions from 1-10 base pairs in size. Variants greater than 10 base pairs may be detected, but the analytical sensitivity may be reduced.

LIMITATIONS: A negative result does not exclude Crigler-Najjar or Gilbert syndromes. Other genetic factors and nongenetic factors may contribute to irinotecan toxicity and efficacy. This test only detects variants within the coding regions, intron-exon boundaries, and promoter region of the UGT1A1 gene. Regulatory region variants other than the (TA)_nTAA promoter region, and deep intronic variants will not be identified. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Diagnostic errors can occur due to rare sequence variations. In some cases, variants may not be identified due to technical limitations in the presence of pseudogenes, repetitive, or homologous regions. This test is not intended to detect low-level mosaic or somatic variants, gene conversion events, complex inversions, translocations,

H=High, L=Low, *=Abnormal, C=Critical

mitochondrial DNA (mtDNA) variants, or repeat expansions. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplant. Noncoding transcripts were not analyzed.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
UGT1A1 Specimen	24-267-400361	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
UGT1A1 Interp	24-267-400361	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical